Estimating the public health impact of the effect of herpes simplex virus suppressive therapy on plasma HIV-1 viral load

AIDS

Volumn 23, Issue 8, 2009, Pages 1005-1013

  Baggaley, Rebecca F ^a   Griffin, Jamie T ^a   Chapman, Ruth ^b   Hollingsworth, T Déirdre ^a   Nagot, Nicolas ^c   Delany, Sinead ^d   Mayaud, Philippe ^b   De Wolf, Frank ^e   Fraser, Christophe ^a   Ghani, Azra C ^a   Weiss, Helen A ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIV MONTPELLIER   (France)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Acyclovir; Herpes simplex virus type 2; HIV; Suppressive therapy; Transmission; Valacyclovir; Viral load

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE DURATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL; SEXUAL TRANSMISSION; TREATMENT DURATION; VIRUS LOAD;

AFRICA SOUTH OF THE SAHARA; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; MALE; PUBLIC HEALTH; RNA, VIRAL;

EID: 67049144187     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832aadf2     Document Type: Article

References (31)

1. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73-83.
2. Corey L, Wald A, Celum CL, Quinn TC. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004; 35:435-445.
3. McClelland RS, Wang CC, Overbaugh J, Richardson BA, Corey L, Ashley RL, et al. Association between cervical shedding of herpes simplex virus and HIV-1. AIDS 2002; 16:2425-2430.
4. Freeman EE, Orroth KK, White RC, Glynn JR, Bakker R, Boily MC, et al. Proportion of new HIV infections attributable to herpes simplex 2 increases over time: simulations of the changing role of sexually transmitted infections in sub-Saharan African HIV epidemics. Sex Transm Infect 2007; 83 (Suppl 1): i17-i24.
5. Abu-Raddad LJ, Magaret AS, Celum C, Wald A, Longini IM Jr, Self SG, Corey L. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS ONE 2008; 3:e2230.
6. Mbopi-Keou FX, Gresenguet G, Mayaud P, Weiss HA, Gopal R, Matta M, et al. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J Infect Dis 2000; 182: 1090-1096.
7. WHO. Herpes simplex virus type 2: programmatic and research priorities in developing countries. London, UK: Report of a WHO/UNAIDS/LSHTM workshop; 14-16 February 2001. WHO/HIV-AIDS/2001.05 ISBN 92-9173-144-7.
8. Delany S, Mlaba N, Clayton T, Akpomiemie G, Capovilla A, Legoff J, et al. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/H1V-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS 2009; 23:461-469.
9. Nagot N, Ouedraogo A, Foulongne V, Konate I, Weiss HA, Vergne L, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007; 356:790-799.
10. Tanton C, Watson-Jones D, Rusizoka M, Le Goff J, Weiss H, Lefebvre C, et al. A randomized controlled trial in Tanzania to assess the impact of HSV2 suppressive therapy on genital HIV viral load among HSV2 and HIV1 seropositive women [abstract TUPEC011]. In: International AIDS Society Conference; 22-25 July 2007; Sydney, Australia.
11. Cowan FM, Pascoe S, Barlow K, Langhaug L, Jaffar S, Hargrove J, et al. A randomised placebo controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers. Sex Transm Infect 2008; 84:548-553.
12. Ouedraogo A, Nagot N, Vergne L, Konate I, Weiss HA, Defer MC, et al. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. AIDS 2006; 20:2305-2313.
13. Zuckerman RA, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, Zuniga R, et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis 2007; 196:1500-1508.
14. Baeten JM, Strick LB, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/ HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis 2008; 198:1804-1808.
15. Dunne EF, Whitehead S, Sternberg M, Thepamnuay S, Leela-wiwat W, McNicholl JM, et al. Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand. J Acquir Immune Defic Syndr 2008; 49:77-83.
16. Fideli US, Allen SA, Musonda R, Trask S, Hahn BH, Weiss H, et al. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses 2001; 17:901-910.
17. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-929.
18. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-1170.
19. + T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS 1997; 11:1799-1806.
20. Fraser C, Hollingsworth TD, Chapman R, de Wolf F, Hanage WP. Variation in HIV-1 set-point viral load: epidemiological analysis and an evolutionary hypothesis. Proc Natl Acad Sci USA 2007; 104:17441-17446.
21. Efron B, Tibshirani R, editors. An introduction to the bootstrap. Florida: Chapman & Hall; 1998.
22. Donnelly CA, Bartley LM, Ghani AC, Le Fevre AM, Kwong GP, Cowling BJ, et al. Gender difference in HIV-1 RNA viral loads. HIV Med 2005; 6:170-178.
23. Napravnik S, Poole C, Thomas JC, Eron JJ Jr. Gender difference in HIV RNA levels: a meta-analysis of published studies. J Acquir Immune Defic Syndr 2002; 31:11-19.
24. Duffus WA, MerminJ, Bunnell R, Byers RH, Odongo G, Ekwaru P, Downing R. Chronic herpes simplex virus type-2 infection and HIV viral load. Int J STD AIDS 2005; 16:733-735.
25. Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Moretlwe S, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371:2109-2119.
26. Watson-Jones D, Weiss HA, Rusizoka M, Changalucha J, Bais-ley K, Mugeye K, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008; 358:1560-1571.
27. Geskus RB, Prins M, Hubert JB, Miedema F, Berkhout B, Rouzioux C, et al. The HIV RNA setpoint theory revisited. Retrovirology 2007; 4:65.
28. loannidis JP, Collier AC, Cooper DA, Corey L, Fiddian AP, Gazzard BG, et al. Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis 1998; 178:349-359.
29. McMahon MA, Siliciano JD, Lai J, Liu JO, Stivers JT, Siliciano RF, Kohli RM. The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multi-drug resistance mutation. J Biol Chem 2008; 283:31289-31293.
30. Modjarrad K, Chamot E, Vermund SH. Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. AIDS 2008; 22:2179-2185.
31. Wilson DP, Law MG, Grulich AE, Cooper DA, Kaldor JM. Relation between HIV viral load and infectiousness: a model-based analysis. Lancet 2008; 372:314-320.